指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

新型冠状病毒感染抗病毒药物联合使用中国专家共识

Chinese expert consensus on the combined use of antiviral drugs for novel coronavirus infection.
指南 / 共识 · Biosci Trends · 2025-08-26
一句话结论专家共识提出,对部分免疫抑制、移植后等特殊患者,当病毒清除为主要目标时,可考虑联合使用小分子抗病毒药物以尽早清除病毒。

新型冠状病毒持续突变,对现有抗病毒策略构成挑战;临床观察到,奈玛特韦/利托那韦(NTV/r)等治疗后病毒载量反弹、重症和急诊患者需快速清除病毒,提示单药方案可能抑制强度不足。专家组由感染、呼吸、重症和临床药学等学科专家组成,经系统文献检索并聚焦关键问题,形成《口服小分子抗病毒药物联合治疗COVID-19专家共识》。共识指出,不同机制抗病毒药物联合可能疗效更好且不显著增加不良反应,尤其对免疫抑制、移植后等常规治疗后核酸不易转阴、病毒清除仍为主要目标的特殊患者,联合小分子抗病毒药有助于尽早清除病毒并尝试提高挽救治疗成功率。

要点

  • 对免疫抑制、移植后等特殊患者,常规治疗后COVID-19核酸不易转阴且病毒清除仍为主要目标时,可考虑联合小分子抗病毒药以尽早清除病毒。
  • 临床观察到不同机制抗病毒药联合可能疗效更好且不显著增加不良反应,尤其适用于上述特殊患者。
  • NTV/r等药物治疗后病毒载量反弹、重症和急诊患者需快速清除病毒,提示单药方案可能抑制强度不足。
  • 共识由感染、呼吸、重症和临床药学等多学科专家经系统文献检索形成,供临床实践参考。

适用人群与场景

  • 免疫抑制、移植后或其他特殊患者,常规治疗后COVID-19核酸不易转阴且病毒清除仍为主要目标时。
  • 重症和急诊患者,需快速清除病毒时。

处置流程与药物剂量

  • 对免疫抑制、移植后等特殊患者,常规治疗后核酸不易转阴且病毒清除仍为主要目标时,可考虑联合使用小分子抗病毒药物以尽早清除病毒并尝试提高挽救治疗成功率。
  • 临床观察到不同机制抗病毒药物联合可能疗效更好且不显著增加不良反应。

研究设计与关键结果

  • 专家组由感染、呼吸、重症和临床药学等学科专家组成,经系统文献检索并聚焦关键问题,形成《口服小分子抗病毒药物联合治疗COVID-19专家共识》。

证据类型、等级与局限

  • 证据类型:专家共识。
  • 共识基于循证医学并结合中国现状制定。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对免疫抑制、移植后等特殊患者,常规治疗后核酸不易转阴且病毒清除仍为主要目标时,可考虑联合小分子抗病毒药以尽早清除病毒。
  • 临床观察到不同机制抗病毒药联合可能疗效更好且不显著增加不良反应。
  • NTV/r等治疗后病毒载量反弹、重症和急诊患者需快速清除病毒,提示单药方案可能抑制强度不足。

指南或共识出处

  • 《新型冠状病毒感染抗病毒药物联合使用中国专家共识》(Expert Consensus on Combined Use of Oral Small-molecule Antivirals to Treat COVID-19),发表于Biosci Trends。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The persistent mutation of the novel coronavirus (SARS-CoV-2) not only remains a threat to human health but also continues to challenge existing antiviral therapeutic strategies. In current clinical practice, the resistance of novel coronavirus to antivirals, the rebound of viral load after treatment with drugs such as nirmatrelvir/ritonavir (NTV/r), and the urgent need for rapid clearance of the virus in the management of critically and emergently ill patients suggest that the existing single-drug regimens may have limitations and that the intensity of suppression may be insufficient in some cases. In clinical practice, we have observed that a combination of antivirals with different mechanisms of action can result in better efficacy and not significantly increase adverse drug reactions (ADRs). For some immunosuppressed, post-transplantation, or other special patients in particular, such as those in whom COVID-19 nucleic acids tended not to be negative after conventional treatment, when virus clearance is still the main goal, the combination of small-molecule antivirals can help to clear the virus as early as possible and attempt to improve the success rate of salvage. Based on evidence-based medicine and in light of the current situation of China, we assembled experts from disciplines such as infectious diseases, respiratory medicine, critical care medicine, and clinical pharmacy into a group to carry out a systematic literature search and identify key issues and to put forward relevant recommendations to reach an Expert Consensus on Combined Use of Oral Small-molecule Antivirals to Treat COVID-19, which is intended to serve as a reference for clinical practice.

来源:Biosci Trends,查看原文。版权归原作者所有。

参考来源

  1. Chen G, Yuan J, Wei Y, et al. Chinese expert consensus on the combined use of antiviral drugs for novel coronavirus infection. Biosci Trends. 2025. PMID: 40866234. doi:10.5582/bst.2025.01244

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。